Market Cap 400.88B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 24.00
Forward PE 21.30
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 18,968,800
Avg Vol 5,886,242
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 71%
Beta 0.36
Analysts Strong Sell
Price Target $245.84

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
NeverFadeTheOracle
NeverFadeTheOracle Dec. 22 at 1:59 PM
$ARWR Named Top Pick at Piper 2026 $ABBV $AMGN $TEVA
0 · Reply
KingdomTrading
KingdomTrading Dec. 22 at 1:48 PM
$ABBV 📈 Moderate Outlook Price: $226.82 Entry: $226.82 Target: $220.64 Expected Move: -2.72% Timeframe: 8 days The content provided on https://stocksurger.com/ is for informational purposes only and does not constitute a recommendation to buy or sell any security.
0 · Reply
GoodTidings
GoodTidings Dec. 22 at 1:41 PM
$SLS I understand that $PFE is somehow in the picture... That extends the favourable $ABBV and the other player $MRK 🤔🤔🤔
0 · Reply
Longbuy1
Longbuy1 Dec. 21 at 5:19 PM
$SLS Lol, take off your stop losses, shorts are going to try to get your shares cheap. (Every morning there is a drop) Phase 3 GPS readout is any day. The data, which almost all us expect to be good, combined with the better than expected SLS phase 2 trial results; so good the FDA personally requested a more controlled study with more recently diagnosed AML patients to enroll. 217M float, warrants are done and exercised, this is going to go into a a bidding war between $PFE $ABBV $MRK 10 billion? 25 billion who knows? Angelo cancelled his meeting with Pfizer CEO. Maybe there's already a buyer. You can take your 35% gain or wait for the 1000%.
1 · Reply
1iquid
1iquid Dec. 21 at 5:53 AM
💎 Liquid® Live Actionable Trade Asset: $ABBV Contracts: $ABBV January 15, 2027 $230 Calls Scale in: $21.70- $26.52 Scale out: $84.39-$144.68 Profit Potential : 136% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 21 at 2:21 AM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 09 2026 Buy in Price: $3.75 - $3.80 Sell Price: $6.00 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
MetalinMaybach
MetalinMaybach Dec. 20 at 7:23 PM
$ABBV NGENF is getting ready to list with Nasdaq very soon. This is mainly focused in the SCI space but has applications in other CNS diseases as shown in preclinical trials. If it lists this will be a good opportunity to capitalize on benefits of more exposure.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 20 at 7:22 PM
$SLS $ABBV 23% Fatal Adverse Reactions - FATAL - and 83% Rate of Serious Adverse reactions in Newly Diagnosed AML Patients. Abbvie terminated the VEN AZA VIALE-M and the VIALE-T Maintenance trials for First Remission and Post Stem Cell Transplant patients - due to toxicity. The Toxicity is MORE Harmful to AML Second Remission Patients. VEN+AZA - BAT for the REGAL trial is not effective maintenance treatment, for post R/R AML patients obtaining a Second Remission (CR2) and who are Ineligible for a transplant operation. VEN AZA is Toxic. BAT for REGAL Control Patient's Toxic - its important as people consider what BAT is and isn't.
0 · Reply
1iquid
1iquid Dec. 20 at 5:56 AM
OptionWizards Tip (education only): Start with defined-risk strategies like vertical spreads on stocks such as PLTR, COST, or ABBV to help manage potential… $PLTR $COST $ABBV Not financial advice.
0 · Reply
DefenseMania
DefenseMania Dec. 20 at 2:47 AM
$MDT interesting Medtronic bought out MiniMed about 25 years ago at the time it was a publicly traded company MNMD And now they’re going to spin it off again lol Curious to see what the shareholders will get . $GILD $ABBV $ISRG
0 · Reply
Latest News on ABBV
AbbVie: Unique Mix Of Growth And Value

Dec 10, 2025, 8:01 PM EST - 11 days ago

AbbVie: Unique Mix Of Growth And Value


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 23 days ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS


AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 5 weeks ago

AbbVie Shares Rise To Intraday High After Key Trading Signal


AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 5 weeks ago

AbbVie Has Many Bullish Attributes (Technical Analysis)


Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 6 weeks ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 7 weeks ago

Best Dividend Aristocrats For November 2025

ABT ADM ADP AMCR AOS ATO BDX


AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript

Oct 31, 2025, 3:56 PM EDT - 7 weeks ago

AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript


AbbVie: Why Q3 Confirms Its Immunology Dominance

Oct 31, 2025, 10:39 AM EDT - 7 weeks ago

AbbVie: Why Q3 Confirms Its Immunology Dominance


AbbVie Lifts Profit Outlook as Sales Rise

Oct 31, 2025, 8:42 AM EDT - 7 weeks ago

AbbVie Lifts Profit Outlook as Sales Rise


AbbVie Reports Third-Quarter 2025 Financial Results

Oct 31, 2025, 7:49 AM EDT - 7 weeks ago

AbbVie Reports Third-Quarter 2025 Financial Results


Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 7 weeks ago

Best Dividend Kings: October 2025

ABM ABT ADM ADP AWR BDX BKH


AbbVie: Deep Discount Before Earnings

Oct 28, 2025, 11:28 AM EDT - 7 weeks ago

AbbVie: Deep Discount Before Earnings


NeverFadeTheOracle
NeverFadeTheOracle Dec. 22 at 1:59 PM
$ARWR Named Top Pick at Piper 2026 $ABBV $AMGN $TEVA
0 · Reply
KingdomTrading
KingdomTrading Dec. 22 at 1:48 PM
$ABBV 📈 Moderate Outlook Price: $226.82 Entry: $226.82 Target: $220.64 Expected Move: -2.72% Timeframe: 8 days The content provided on https://stocksurger.com/ is for informational purposes only and does not constitute a recommendation to buy or sell any security.
0 · Reply
GoodTidings
GoodTidings Dec. 22 at 1:41 PM
$SLS I understand that $PFE is somehow in the picture... That extends the favourable $ABBV and the other player $MRK 🤔🤔🤔
0 · Reply
Longbuy1
Longbuy1 Dec. 21 at 5:19 PM
$SLS Lol, take off your stop losses, shorts are going to try to get your shares cheap. (Every morning there is a drop) Phase 3 GPS readout is any day. The data, which almost all us expect to be good, combined with the better than expected SLS phase 2 trial results; so good the FDA personally requested a more controlled study with more recently diagnosed AML patients to enroll. 217M float, warrants are done and exercised, this is going to go into a a bidding war between $PFE $ABBV $MRK 10 billion? 25 billion who knows? Angelo cancelled his meeting with Pfizer CEO. Maybe there's already a buyer. You can take your 35% gain or wait for the 1000%.
1 · Reply
1iquid
1iquid Dec. 21 at 5:53 AM
💎 Liquid® Live Actionable Trade Asset: $ABBV Contracts: $ABBV January 15, 2027 $230 Calls Scale in: $21.70- $26.52 Scale out: $84.39-$144.68 Profit Potential : 136% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 21 at 2:21 AM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 09 2026 Buy in Price: $3.75 - $3.80 Sell Price: $6.00 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
MetalinMaybach
MetalinMaybach Dec. 20 at 7:23 PM
$ABBV NGENF is getting ready to list with Nasdaq very soon. This is mainly focused in the SCI space but has applications in other CNS diseases as shown in preclinical trials. If it lists this will be a good opportunity to capitalize on benefits of more exposure.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 20 at 7:22 PM
$SLS $ABBV 23% Fatal Adverse Reactions - FATAL - and 83% Rate of Serious Adverse reactions in Newly Diagnosed AML Patients. Abbvie terminated the VEN AZA VIALE-M and the VIALE-T Maintenance trials for First Remission and Post Stem Cell Transplant patients - due to toxicity. The Toxicity is MORE Harmful to AML Second Remission Patients. VEN+AZA - BAT for the REGAL trial is not effective maintenance treatment, for post R/R AML patients obtaining a Second Remission (CR2) and who are Ineligible for a transplant operation. VEN AZA is Toxic. BAT for REGAL Control Patient's Toxic - its important as people consider what BAT is and isn't.
0 · Reply
1iquid
1iquid Dec. 20 at 5:56 AM
OptionWizards Tip (education only): Start with defined-risk strategies like vertical spreads on stocks such as PLTR, COST, or ABBV to help manage potential… $PLTR $COST $ABBV Not financial advice.
0 · Reply
DefenseMania
DefenseMania Dec. 20 at 2:47 AM
$MDT interesting Medtronic bought out MiniMed about 25 years ago at the time it was a publicly traded company MNMD And now they’re going to spin it off again lol Curious to see what the shareholders will get . $GILD $ABBV $ISRG
0 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 19 at 9:33 PM
🚀 New Signal ✅ 🏛️ $ABBV 🗓️ Dec 19, 2025 💵 Entry: $226.72 🎯 Target (Opt.): $232.07 (+2.36%) 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
PickAlpha
PickAlpha Dec. 19 at 8:40 PM
PickAlpha Mid-Day — Trump locks in pharma price pacts President Trump said the White House reached pricing deals with nine drugmakers, taking the total to 14 of 17 targeted this summer. The agreements aim to cut prices for Medicaid, push direct-to-consumer discounted sales (via a planned TrumpRX site), and tie some new US launch prices closer to overseas levels — in exchange for a 3-year reprieve from threatened tariffs. Names cited include NVS / BMY / GILD / AMGN / GSK / SNY / MRK; holdouts: ABBV / JNJ / REGN. Our view is: this is policy-driven margin risk packaged as “tariff relief.” The market will reprice on how enforceable the confidential terms are and whether “MFN-style” pricing spreads beyond Medicaid/DTC into broader commercial channels. Near-term, the uncertainty premium rises for the remaining holdouts (they’re next in line), while “deal signers” get headline relief but face a multiple cap until the revenue/mix impact is quantified. Tickers $MRK $ABBV $JNJ
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 19 at 7:51 PM
Hedge Alert Live - Protect Your Portfolio Contract: $ABBV $222.50 Put · DEC 26, 2025 Exp Entry Price: $2.25 - $2.36 Exit Price Target: $3.71 Profit Margin: +65% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
30DeltaSpy
30DeltaSpy Dec. 19 at 7:16 PM
$ABBV $RGNX ☺️
0 · Reply
AlertsAndNews
AlertsAndNews Dec. 19 at 7:01 PM
$GSK $BMY $NVO $ABBV $DJT trump is about to give his conference on drug prices. Here's a live link https://www.youtube.com/watch?v=Zu5uNjx_rpA
1 · Reply
KingdomTrading
KingdomTrading Dec. 19 at 7:00 PM
$ABBV Current: $226.29 Entry: $219.29 Target: $187.86 Potential: -14.3% Horizon: 14 days The content provided on https://stocksurger.com/ is for informational purposes only and does not constitute a recommendation to buy or sell any security.
0 · Reply
GoodTidings
GoodTidings Dec. 19 at 5:38 PM
$SLS Just let the bidding war begin... $ABBV Against $MRK ... 🤔🤔🤔
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:13 PM
Actionable Trade Alert for $ABBV: Market Context: $ABBV is currently trading at $222.82, with an RSI of 42.01 indicating a neutral to slightly bearish momentum. The stock is below both the 30-day MA (227.15) and the 50-day MA (226.75), suggesting potential downward pressure. However, it remains above the 60-day low of $211.69, providing a support level. Directional Bias: The current price action indicates a potential rebound opportunity as it approaches the 60-day low. The ATR of 4.32 suggests moderate volatility, allowing for reasonable profit targets. Trade Plan: - Suggested Entry: $222.50 - Stop Loss: $210.00 (5.5% below entry) - Take Profit Targets: 1. $230.00 (3.3% gain) 2. $235.00 (5.6% gain) 3. $260.00 (16.8% gain) This trade plan offers a risk-reward ratio that aligns with a potential 17% ROI on the third target. Monitor closely for price action around support levels. https://privateprofiteers.com
0 · Reply
StocktwitsNews
StocktwitsNews Dec. 19 at 11:52 AM
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report $ABBV $MRK $GILD $NVS $REGN https://stocktwits.com/news/equity/markets/abbvie-merck-top-drugmakers-lower-us-drug-prices-trump-mfn-deal/cLeitzkREsG
0 · Reply
CarlosLacombe
CarlosLacombe Dec. 19 at 11:22 AM
$ABBV $MRK $BMY $GILD AbbVie, Merck, Bristol Meyers Squibb and Gilead to announce US drug price deals
0 · Reply
LiveSquawk
LiveSquawk Dec. 19 at 11:14 AM
Several Top Drugmakers To Lower US Prices For Some Drugs – RTRS Sources $ABBV $MRK $BMY $GILD https://www.reuters.com/legal/litigation/several-top-drugmakers-lower-us-prices-some-drugs-sources-2025-12-19/
0 · Reply
Longbuy1
Longbuy1 Dec. 19 at 9:01 AM
$SLS this. $ABBV $PFE 1/12/26 expect some big PR's before then.
1 · Reply